{"DataElement":{"publicId":"7796122","version":"1","preferredName":"Gleason Score for Prostate Cancer Tertiary Gleason Pattern Number","preferredDefinition":"A value capturing the percentage of the tumor displaying the third most prevalent grade of cancer cells, occupying less than 5% of the tumor.","longName":"2782937v1.0:5699360v1.0","context":"MCL","contextVersion":"1","DataElementConcept":{"publicId":"2782937","version":"1","preferredName":"Gleason Score Tertiary Gleason Score for Prostate Cancer","preferredDefinition":"A system of grading prostate cancer cells to determine the best treatment and to predict how well a person is likely to do. A low Gleason score means the cancer cells are very similar to normal prostate cells; a high Gleason score means the cancer cells are very different from normal. _definition pending","longName":"2547908v1.0:2431266v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2547908","version":"1","preferredName":"Gleason Score for Prostate Cancer","preferredDefinition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","longName":"C28084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gleason Score for Prostate Cancer","conceptCode":"C28084","definition":"The score derived from universally embraced prostate cancer grading system developed by Dr. Donald F. Gleason in 1977. The system provides a reproducible description of the glandular architecture of prostate tissue to which a pathologist assigns a score depending primarily on the microscopic patterns of cancerous glands and cell morphology. The system correlates well with behavior at the extremes: Gleason 1+1 tumors are the most well differentiated, slowly growing and rarely spread; Gleason 4+5 tumors are the most poorly differentiated, often widely metastatic at the time of diagnosis. In the commoner intermediate grade tumors, however, behavior is extremely variable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"23681B08-081C-19C0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-11-29","modifiedBy":"SBREXT","dateModified":"2017-08-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2431266","version":"1","preferredName":"Tertiary Gleason Score for Prostate Cancer","preferredDefinition":"definition pending","longName":"C48605","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tertiary Gleason Pattern","conceptCode":"C48605","definition":"Prostate carcinoma patterns occupying less than 5% of the tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"05DCEA00-2431-36A2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-18","endDate":null,"createdBy":"UMLLOADER_CAP","dateCreated":"2005-11-18","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5691D3A5-7FED-1EA1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-10","endDate":null,"createdBy":"UMLLOADER_CATISSUE","dateCreated":"2008-09-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9/28/10 Released for use in caTissue Suite version 1.1 and/or 1.2 per owners direction.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5699360","version":"1","preferredName":"Tertiary Gleason Pattern Number","preferredDefinition":"Prostate carcinoma patterns occupying less than 5% of the tumor._A numeral or string of numerals expressing value, quantity, or identification.","longName":"5699360v1.0","context":"MCL","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5699359","version":"1","preferredName":"Tertiary Gleason Pattern Number","preferredDefinition":"Prostate carcinoma patterns occupying less than 5% of the tumor.:A numeral or string of numerals expressing value, quantity, or identification. ","longName":"C48605:C25337","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tertiary Gleason Pattern","conceptCode":"C48605","definition":"Prostate carcinoma patterns occupying less than 5% of the tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Number","conceptCode":"C25337","definition":"A numeral or string of numerals expressing value, quantity, or identification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A39324C-A0F3-57B4-E053-F662850A9803","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-03-08","modifiedBy":"ONEDATA","dateModified":"2017-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"4A39324C-A104-57B4-E053-F662850A9803","latestVersionIndicator":"Yes","beginDate":"2017-03-08","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-03-08","modifiedBy":"COLBERTM","dateModified":"2022-03-15","changeDescription":"3/15/22 mr Released per MCL SME.   10/6/21 mr Repurposed draft new EDRN VD for MCL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506113","version":"1","longName":"Prostate","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781145","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001794","version":"1","longName":"Prostate PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"percent_gleason_pattern_4","type":"MCL Alt Name","context":"MCL"}],"ReferenceDocuments":[{"name":"Percent Gleason pattern 4 (te","type":"Preferred Question Text","description":"Percent Gleason pattern 4 (tertiary pattern)","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"prostate_v0_13aug2020.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CDB459AB-FA74-2075-E053-4EBD850A83B2","latestVersionIndicator":"Yes","beginDate":"2021-10-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2021-10-06","modifiedBy":"COLBERTM","dateModified":"2022-02-24","changeDescription":"2/24/22 mr Released per SME.   10/21/21 mr Updated definition and long name.  10/13/21 mr Updated definition.  10/6/21 mr Created for MCL PCA prostate per DCT. Repurposed draft new EDRN VD.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}